公开(公告)号：US12285483B2

公开(公告)日：2025-04-29

申请号：US18269284

申请日：2021-10-16

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher Bradford Fox

IPC: A61K39/39 ,  A61K9/10 ,  A61K9/107 ,  A61K39/145 ,  A61K47/22 ,  A61P37/04 ,  A61K39/00

Abstract: This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.

公开(公告)号：US20240140997A1

公开(公告)日：2024-05-02

申请号：US18407367

申请日：2024-01-08

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. REED ,  Rhea N. COLER ,  Gregory C. IRETON ,  Sylvie BERTHOLET

IPC: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/569 ,  G01N33/68

CPC classification number: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/5695 ,  G01N33/68 ,  A61K2039/55561

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US11344619B2

公开(公告)日：2022-05-31

申请号：US16098615

申请日：2017-05-11

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. Fox

IPC: A61K39/395 ,  A61K39/39 ,  A61K39/04 ,  A61K39/12 ,  C07K14/705 ,  A61K35/76 ,  A61K45/06 ,  A61P31/12 ,  A61P33/04 ,  A61P31/06 ,  A61P35/00 ,  A61K39/00

Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.